202 related articles for article (PubMed ID: 27744053)
1. Olmesartan, an angiotensin II receptor blocker inhibits the progression of cataract formation in cadmium chloride induced hypertensive albino rats.
Choudhary R; Bodakhe SH
Life Sci; 2016 Dec; 167():105-112. PubMed ID: 27744053
[TBL] [Abstract][Full Text] [Related]
2. Magnesium taurate prevents cataractogenesis via restoration of lenticular oxidative damage and ATPase function in cadmium chloride-induced hypertensive experimental animals.
Choudhary R; Bodakhe SH
Biomed Pharmacother; 2016 Dec; 84():836-844. PubMed ID: 27728893
[TBL] [Abstract][Full Text] [Related]
3. Role of the renin-angiotensin system in the development of cataract formation in angiotensin-II-induced experimental rats.
Choudhary R; Shree J; Singh A; Bodakhe SH
J Biochem Mol Toxicol; 2021 Jul; 35(7):e22789. PubMed ID: 33847027
[TBL] [Abstract][Full Text] [Related]
4. Role of Nitric Oxide in the Development of Cataract Formation in CdCl2-induced Hypertensive Animals.
Yadav A; Choudhary R; Bodakhe SH
Curr Eye Res; 2018 Dec; 43(12):1454-1464. PubMed ID: 30015520
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
6. Hypertension potentiates cataractogenesis in rat eye through modulation of oxidative stress and electrolyte homeostasis.
Khan SA; Choudhary R; Singh A; Bodakhe SH
J Curr Ophthalmol; 2016 Sep; 28(3):123-30. PubMed ID: 27579456
[TBL] [Abstract][Full Text] [Related]
7. Effects of a novel isoflavonoid from the stem bark of Alstonia scholaris against fructose-induced experimental cataract.
Soni P; Choudhary R; Bodakhe SH
J Integr Med; 2019 Sep; 17(5):374-382. PubMed ID: 31227424
[TBL] [Abstract][Full Text] [Related]
8. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
[TBL] [Abstract][Full Text] [Related]
9. Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: in vivo and in vitro evaluation.
Agarwal R; Iezhitsa I; Awaludin NA; Ahmad Fisol NF; Bakar NS; Agarwal P; Abdul Rahman TH; Spasov A; Ozerov A; Mohamed Ahmed Salama MS; Mohd Ismail N
Exp Eye Res; 2013 May; 110():35-43. PubMed ID: 23428743
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
Gounder VK; Arumugam S; Arozal W; Thandavarayan RA; Pitchaimani V; Harima M; Suzuki K; Nomoto M; Watanabe K
Int Immunopharmacol; 2014 Feb; 18(2):282-9. PubMed ID: 24291173
[TBL] [Abstract][Full Text] [Related]
11. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
14. Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress.
Shimizu S; Saito M; Oiwa H; Ohmasa F; Tsounapi P; Oikawa R; Dimitriadis F; Martin DT; Satoh I; Kinoshita Y; Tomita S
Neurourol Urodyn; 2014 Mar; 33(3):350-7. PubMed ID: 23775684
[TBL] [Abstract][Full Text] [Related]
15. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
17. Reduction of oxidative-nitrosative stress underlies anticataract effect of topically applied tocotrienol in streptozotocin-induced diabetic rats.
Abdul Nasir NA; Agarwal R; Sheikh Abdul Kadir SH; Vasudevan S; Tripathy M; Iezhitsa I; Mohammad Daher A; Ibrahim MI; Mohd Ismail N
PLoS One; 2017; 12(3):e0174542. PubMed ID: 28350848
[TBL] [Abstract][Full Text] [Related]
18. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
19. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
Cal LA; Maso LD; Caielli P; Pagnin E; Fusaro M; Davis PA; Pessina AC
Blood Press; 2011 Dec; 20(6):376-82. PubMed ID: 21504378
[TBL] [Abstract][Full Text] [Related]
20. The role of olmesartan medoxomil in the management of hypertension.
Unger T; McInnes GT; Neutel JM; Böhm M
Drugs; 2004; 64(24):2731-9. PubMed ID: 15563246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
